Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dimed Distribuidora de Medicamentos's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was R$0.18.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was R$0.86.
During the past 12 months, Dimed Distribuidora de Medicamentos's average earnings per share (NRI) Growth Rate was 53.80% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 15.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 17.00% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
BSP:PNVL3'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.1 Med: 11.6 Max: 54.5
Current: 15.8
During the past 13 years, Dimed Distribuidora de Medicamentos's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 54.50% per year. The lowest was -9.10% per year. And the median was 11.60% per year.
BSP:PNVL3's 3-Year EPS without NRI Growth Rate is ranked better than 60.89% of 790
companies
in the Drug Manufacturers industry
Industry Median: 9.6
vs BSP:PNVL3: 15.80
Dimed Distribuidora de Medicamentos (BSP:PNVL3) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Dimed Distribuidora de Medicamentos EPS without NRI Related Terms
Dimed Distribuidora de Medicamentos EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos EPS without NRI Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: EPS without NRI Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's PE Ratio without NRI falls into.
Dimed Distribuidora de Medicamentos EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a EPS without NRI of R$0.86 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Dimed Distribuidora de Medicamentos and its competitors. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #309 out of 790 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Dimed Distribuidora de Medicamentos' EPS without NRI too high?
Dimed Distribuidora de Medicamentos' current EPS without NRI is R$0.86. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #309 out of 790 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' EPS without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #309 out of 790 companies for EPS without NRI. This puts Dimed Distribuidora de Medicamentos in the upper half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 790 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current EPS without NRI is R$0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.67, compared to a current price of R$10.97 — trading 19.8% below its estimated fair value. The current EPS without NRI is R$0.86. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current EPS without NRI is R$0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$10.97 is trading 19.8% below its estimated GF Value™ of R$13.67.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
EPS without NRI: R$0.86
GF Value™: R$13.67 vs. price of R$10.97 (19.8% below fair value)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed Distribuidora de Medicamentos Business Description
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score
Get the complete analysis for BSP:PNVL3
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
